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Summary
A serious obstacle to successful treatment of estrogen receptor (ER)-positive human breast cancer is cell resistance to
tamoxifen (TAM) therapy. Here we show that the electrophile disulfide benzamide (DIBA), an ER zinc finger inhibitor, blocks
ligand-dependent and -independent cell growth of TAM-resistant breast cancer in vitro and in vivo. Such inhibition depends
on targeting disruption of the ER DNA-binding domain and its communication with neighboring functional domains,
facilitating ERa dissociation from its coactivator AIB1 and concomitant association with its corepressor NCoR bound to
chromatin. DIBA does not affect phosphorylation of HER2, MAPK, AKT, and AIB1, suggesting that DIBA-modified ERa
may induce a switch from agonistic to antagonistic effects of TAM on resistant breast cancer cells.Introduction
The selective estrogen receptor modulator (SERM) tamoxifen
(TAM), which binds to the estrogen receptor a (ERa) and partially
inhibits its activity, is the most prolific therapeutic drug for the
treatment of ER-positive breast cancer (Osborne, 1998). Adju-
vant therapy studies of TAM show a 40%–50% reduction in
the odds of recurrence and reduced mortality. Unfortunately,
advanced breast cancers that initially respond well to TAM
eventually become refractory to this compound (McDonnell
and Norris, 2002; Jordan, 2004; Osborne et al., 2003; Shou
et al., 2004).
ER functions in the nucleus as a transcriptional regulator of
specific genes (Tsai and O’Malley, 1994). The structural organi-
zation of ERa consists of a ligand-independent transcription-
activation domain (AF-1 domain), a DNA-binding domain (DBD),
a ligand-binding domain (LBD), and a ligand-dependent trans-
activation domain (AF-2 domain) (Kumar et al., 1987; RuffCANCER CELL 10, 487–499, DECEMBER 2006 ª2006 ELSEVIER INC. DOet al., 2000). Estrogen binding to ER alters its conformation, trig-
gers receptor dimerization, and directly facilitates binding of the
receptor complex to promoter regions of target genes, including
sites known as estrogen-responsive elements (ERE), or indi-
rectly through transcription factors such as AP-1 (Kushner
et al., 2000). The recruitment of coactivators such as AIB1 and
other proteins with acetyltransferase activity helps to unwind
the chromatin, allowing transcription to occur (Brzozowski
et al., 1997; Glass and Rosenfeld, 2000; Shang et al., 2000;
Shiau et al., 1998; Smith et al., 1997). In contrast, the ER con-
formation induced by the binding of SERMs like TAM favors
the recruitment of corepressors NCoR/SMRT and deacetylases
that inhibit transcriptional activity in TAM-sensitive breast can-
cer cells (Keeton and Brown, 2005; Kurebayashi et al., 2000;
Mak et al., 1999; Osborne et al., 2003; Shou et al., 2004). How-
ever, acquired resistance can be caused by alterations in the ER
signal transduction pathway, converting the inhibitory SERM-
ERa complex to a growth stimulatory signal (Jordan, 2004).S I G N I F I C A N C E
Acquired resistance to antiestrogens is a major challenge to the clinical management of initially endocrine-responsive metastatic
breast cancer. We have previously found that electrophilic DIBA and benzisothiazolone derivatives inhibited TAM-sensitive breast can-
cer cells by preferentially disrupting the vulnerable zinc fingers within the ER DNA-binding domain. Herewe describe howDIBA restores
the antagonistic action of TAM in resistant breast cancer cells through targeted disruption of the ER DNA-binding domain and its inter-
actionwith theproximalN-terminal domain to suppress ligand-dependent and -independent ER transcriptionand influence the recruit-
ment of cofactor to the ER. These results show that small-molecule modification of the ER zinc finger may alter coactivator/corepressor
functions, which are particularly relevant to TAM resistance.I 10.1016/j.ccr.2006.09.015 487
A R T I C L EGrowing evidence indicates that crosstalk between ER and
growth factor receptor signaling pathways (Brockdorff et al.,
2003; Ibrahim and Yee, 2005; Osborne et al., 2005), especially
the insulin-like growth factor receptor (IGFR) family and the epi-
dermal growth factor receptor (EGFR) family (such as cErbB2
[HER2]), is one of the mechanisms for resistance to endocrine
therapy in breast cancer (Schiff et al., 2004). In tumors with
abundant ER, AIB1, and HER2, TAM behaves as an ER agonist
and stimulates tumor growth (Osborne et al., 2005). High levels
of activated AIB1 could reduce the antagonist effects of TAM,
especially in tumors that also overexpress the HER2 receptor
that activates MAPKs. TAM resistance may also be produced
by decreased levels of the corepressor NCoR (Fujita et al.,
2003; Lavinsky et al., 1998; Osborne, 1998).
The ER-DBD contains two nonequivalent Cys4 zinc fingers
(Laity et al., 2001; Ruff et al., 2000; Schoenmakers et al., 1999;
Wikstrom et al., 1999), which function cooperatively in ERdimer-
ization andDNAbinding by stabilizing the secondary and tertiary
structure of the ER-DNA complex (Maynard and Covell, 2001;
Predki and Sarkar, 1992; Schwabe et al., 1993), leading to
ligand-dependent ER transactivation and ER-mediated breast
cancer cell and tumor growth. Moreover, interdomain commu-
nication between the N-terminal AF-1 domain and DBD of
the nuclear receptors helps modulate structure- and ligand-
independent functions of receptors (Brodie and McEwan,
2005; Kumar and Thompson, 2003; Shao et al., 1998; Takimoto
et al., 2003). We have previously found that electrophilic DIBA
and benzisothiazolone derivatives produced anticancer activity
in TAM-sensitive human breast cancer cells by preferentially
disrupting the vulnerable ER zinc fingers, thus blocking ER
DNA binding and transactivation (Wang et al., 2004). Since this
anti-breast-cancer strategy targeted ER at the level of its DNA
binding, rather than the classical antagonism of estrogen bind-
ing, it is relevant to explore whether DIBA has the capacity to
inhibit the growth of TAM-resistant breast cancer cells.
In this report, we investigated how DIBA restored the antago-
nist action of TAM on breast cancer, which was dependent on
targeting disruption of the ER DNA-binding domain and its com-
munication with neighboring transcription domains. Moreover,
DIBA reduced ER association with coactivator AIB1 and en-
hanced ER association with corepressor NCoR. These findings
provided the proof of principle for a potential for DIBA applicable
to TAM-resistant breast cancer.
Results
DIBA suppresses TAM-resistant breast cancer
cell growth
First we explored whether DIBA affects estrogen-mediated
growth of TAM-resistant breast cancer cells. MCF-7/LCC2 is
a selective ER-positive, TAM-resistant cell line (Brunner et al.,
1993; Lilling et al., 2000). The specific ER ligand 17b-estradiol
(E2) stimulated [3H]thymidine incorporation in MCF-7/LCC2
and its parent MCF-7 cells, but the degree of stimulation in
MCF-7/LCC2 is significantly less than that observed in E2-
treated MCF-7 cells (Figures 1A and 1B). 4-Hydroxytamoxifen
(4-OH-TAM) significantly inhibited MCF-7 cells, with an ED50
of 0.1 mM. A low dosage of DIBA enhanced TAM sensitivity,
the ED50 deceasing 2-fold (0.05 mM) (Figure 1A). The TAM-resis-
tant cell line MCF-7/LCC2 validated with relative resistance;488however, a small dosage of DIBA (5 mM) restored 4-OH-TAM
sensitivity, achieving over 90% inhibition of E2-driven prolifera-
tion at the lowest dosage tested of 4-OH-TAM (0.05 mM).
Similarly, DIBA inhibited cell proliferation of MCF-7/HER2-18
(Figure 1C), another TAM-resistant MCF-7 derivative engi-
neered to overexpress HER2 (Benz et al., 1993), and different
types of ER-positive and TAM-resistant breast carcinoma cell
lines including BT474 (Figure 1D), which expresses ER and is
naturally gene amplified for HER2 and AIB1 (Lin et al., 1990;
Anzick et al., 1997), and epithelial ZR-75 cells (Figure 1E)
(Hoffmann et al., 2004) in a dose-dependent manner. These
observations suggested that DIBA effectively restored the
antagonist action of TAM on growth of TAM-resistant breast
cancer cells.
In TAM-resistant cells, peptide growth factor signaling path-
ways appear to be important in modifying cell behavior, growth,
and survival (Brockdorff et al., 2003; Ibrahim and Yee, 2005).
Therefore, we examined whether DIBA impacted TAM-resistant
cell growth mediated by stimulation of exogenous peptide
growth factors. MCF-7/LCC2 cells (Figure 1F) were stimulated
by IGF-1 alone or IGF-1 plus 4-OH-TAM. TAM did not block
IGF-1-driven cell proliferation. However, adding DIBA at even
1 mM was sufficient to restore TAM inhibitory functions. These
data demonstrated that DIBA also suppressed TAM-resistant
cell growth mediated by growth factors.
Efficacy of DIBA on TAM-resistant breast cancer
tumor growth in vivo
The in vivo efficacy of the DIBA was tested using nude mice
bearing human MCF-7/LCC2 breast carcinoma xenografts.
4-OH-TAM alone did not significantly affect tumor growth.
DIBA alone resulted in a dose-dependent inhibition of tumor
growth, and a high dose (30 mg/kg) of DIBA reduced tumor vol-
ume to almost 50%. Moreover, treatment with 4-OH-TAM plus
DIBA diminished tumor to undetectable levels (Figure 2A). Histo-
pathological analysis (Figure 2B) showed a typical hypercellular
solid carcinoma invading the dermis and subcutaneum, and the
tumor cells had a high nuclear grade with frequent mitosis in the
control vehicle (upper panel) or 4-OH-TAM alone-treated mice
(middle panel). In contrast, marked reduction in tumor volume,
partial encapsulation by fibrous connective tissue, and no signif-
icant invasion into surrounding skin tissue were observed in the
mice treated with DIBA plus 4-OH-TAM (lower panel). These
tumor cells with a low nuclear grade, focal glandular differentia-
tion, and no frequent mitosis or necrosis were seen under higher
magnification. No apparent toxicity was observed in liver or
kidney in DIBA-treated mice, nor were there any significant
changes in body weight gain compared with control mice
(data not shown). Therefore, the data demonstrate that DIBA
effectively reduces the growth of MCF-7/LCC2 TAM-resistant
tumors in mice.
Synergism between DIBA and TAM
on cell-cycle progression
Using propidium iodide (PI) staining and fluorescence-activated
cell sorting (FACS) analysis, we further evaluated TAM-treated
cells within the cell cycle in the presence of DIBA (Figure 2C).
E2-treated MCF-7/LCC2 cells showed decreased cells in the
G0/G1 phase and an increased percentage of cells in the S
and G2/M phases. Cells treated with TAM had a weak inhibitory
effect on E2, increasing the percentage of cells in S/G2/M. ByCANCER CELL DECEMBER 2006
A R T I C L EFigure 1. DIBA is a potent inhibitor of TAM-resistant breast cancer cell proliferation
A–E: Proliferation of MCF-7 (A), MCF-7/LCC2 (B), MCF-7/HER2-18 (C), BT474 (D), or ZR-75 (E) cells was examined by [3H]thymidine incorporation assay. Starved
cells were treated with DIBA for 2 hr, stimulated with (filled bars) or without (hatched bars) 50 nM E2, incubated with increasing concentrations of 4-OH-TAM,
and analyzed 48 hr later. Data shown represent mean 6 SEM.
F: Proliferation of starved MCF-7/LCC2 cells induced by 50 nM 4-OH-TAM or 5 ng/ml IGF-1 was also examined after treatment with increasing concentrations of
DIBA. Data shown represent mean 6 SEM.contrast, in cells cotreated with E2 plus ICI 182780, the changes
in cell-cycle status and growth induced by E2 were significantly
inhibited. In the presence of DIBA combined with TAM, cell-
cycle phase distribution induced by E2 shows a significant in-
crease (from 60.7% to 81.7%) of cells in the G0/G1 phase, a de-
crease (from 30.1% to 6.4%) in the S phase, a decrease (from
7.9% to 5.4%) in the G2/M phase, and an increase (from 1.2%
to 6.5%) in the sub-G1 phase. Also, DIBA enhanced the inhibi-
tory effect of ICI 182780 on E2-stimulated cell growth. The
FACS data further confirmed that DIBA restored the antagonist
action of TAM on cell proliferation of TAM-resistant breast can-
cer cells analyzed by the [3H]thymidine incorporation assay.CANCER CELL DECEMBER 2006ER is necessary for synergism between DIBA and TAM
To determine whether targeted disruption of ER is necessary for
DIBA to suppress cell growth of TAM-resistant breast cancer
cells, we used BT474, an ER-positive but TAM-resistant breast
cancer cell line, as a model system to examine the effect of de-
pletion of ER on DIBA inhibition of cell growth of TAM-resistant
cells (Figure 3A). The ER expressed in these cells was knocked
down by using ERa-siRNA. The decreased level of ER was
confirmed by western blot (Figure 3A, inset). Under identical
conditions, DIBA rendered TAM inhibition on parent ER-positive
cells, but was not able to sensitize TAM’s suppression of growth
of ER-depleted breast cancer cells. These data suggest that489
A R T I C L EFigure 2. Synergism inhibition between DIBA and
TAM on in vivo tumor growth and cell-cycle pro-
gression
A: Dose-dependent effect of DIBA and 4-OH-
TAM on growth of MCF-7/LCC2 tumor in mice.
Data shown represent mean 6 SEM (n = 10
mice per group).
B: Morphology of MCF-7/LCC2 tumors treated
with vehicle (upper panel), 4-OH-TAM at
20 mg/kg/day (middle panel), or 4-OH-TAM at
20 mg/kg/day plus DIBA at 30 mg/kg (lower
panel).
C: MCF-7/LCC2 cells were synchronized by
serum starvation, pretreated with 5 mM DIBA,
and then stimulated with 50 nM E2, 50 nM TAM,
or 1 mM ICI 182780. Cell-cycle distribution was
examined by PI staining and FACS analysis. The
results represent three independent experiments
(mean 6 SEM).inhibition of DIBA on growth of TAM-resistant breast cancer
cells depends on ER.
DIBA inhibits ER binding to DNA
To clarify whether the DIBA alters estrogen- or TAM-bound ER’s
ability to bind to its cognate ERE in TAM-resistant breast cancer
cells, we performed electrophoreticmobility shift assays (EMSA)
using nuclear extracts obtained from MCF-7/LCC2 cells (Fig-
ure 3B). E2- or 4-OH-TAM-treated cells displayed considerable
ERE DNA-binding complexes, which could be partially super-
shifted with anti-ER, but not normal rabbit serum, confirming
the specificity of these binding complexes. DIBA significantly
decreased (80%) the E2- or TAM-induced ERE DNA-binding
activity. In a similar experiment on androgen receptor (AR) in
MCF-7/LCC2 (Figure 3C), DIBA did not inhibit AR DNA-binding
activity.
Next, we examined whether DIBA affects ER binding to
probes containing the AP-1, a nontypical repeat element. Estro-
gen or TAM induced substantial AP-1 binding activity (Fig-
ure 3D). The complexes were mostly supershifted with
anti-Jun or anti-Fos antibodies. Anti-ER antibody just marginally
decreased such complexes, suggesting that a low amount of ER
may be bound to AP-1 sites under these conditions/cells. More-
over, DIBA did not display an inhibitory effect on E2- or TAM-
stimulated AP-1-binding activity, possibly because ER binding490to DNA is not required for its activity through the nonclassical
AP-1 pathway (Jakacka et al., 2001; Webb et al., 1999). These
data further support the specificity of DIBA influencing ER bind-
ing to DNA.
DIBA blocks occupancy of estrogen target gene
promoters by ERa
We further used chromatin immunoprecipitations (ChIP) to di-
rectly assess whether DIBA impacts ERa binding to promoters
of estrogen target genes. The presence of the specific pro-
moters in the chromatin immunoprecipitates was analyzed by
semiquantitative PCR by using specific pairs of primers span-
ning the estrogen-responsive regions in the pS2, c-Myc, and
cathepsin D (CATD) gene promoters (Figure 3E). Stimulation
with E2 and TAM dramatically increased ERa’s occupancy of
the above three promoters. DIBA remarkably decreased such
occupancy of ERa to the target gene DNA sequences in chro-
matin. By contrast, ERa did not show any interaction with the
distal promoter region (23351 to 23551) of pS2 promoter.
These results suggested DIBA directly influences the ability of
ERa to bind to ERE in the promoter of target genes.
We also used ChIPs to examine whether DIBA affects ER
binding to AP-1 site in a nontypical manner (Figure 3F). Stim-
ulation with E2 and TAM induced a dramatic increase in the
occupancy by c-fos or ERa of the AP-1 site, but not in theCANCER CELL DECEMBER 2006
A R T I C L EFigure 3. ER is necessary for DIBA to sensitize TAM inhibition
A: siRNA-mediated knockdown of ERa alters DIBA-mediated TAM inhibition of resistant cell growth. BT474 cells were transduced with ERa-siRNA or control
vector and incubated for 96 hr. Levels of ERa expression were examined by western blotting (inset). Proliferation of the above transfected cells treated
with DIBA and 4-OH-TAM in the presence of E2 was assayed by [3H]thymidine incorporation. Data shown represent mean 6 SEM.
B–D: DIBA inhibits E2-induced ERE (B), but not ARE (C) or AP-1 (D), DNA binding. MCF-7/LCC2 cells were treated with or without 5 mM DIBA for 2 hr, then stim-
ulated with medium (2), 50 nM E2, or 50 nM 4-OH-TAM (+) for 20 min. Nuclear extracts were incubated in the absence of antibody, aER, aAR, aJun, aFos, or
normal rabbit serum (NRS) in combination with 32P-labeled oligonucleotide probes. Arrows indicate migrational location of each nonsupershifted ER, AR or
AP-1 DNA complex.
E: The recruitment of ERa to the promoters of estrogen-responsive genes. MCF-7/LCC2 cells were treated with or without 5 mM DIBA for 2 hr, then stimulated with
E2, 4-OH-TAM, or IGF-1 for 40 min. Soluble chromatin was prepared and immunoprecipitated with anti-ERa. The final DNA extractions were amplified using pairs
of primers that cover the regions of pS2, CATD, and c-Myc gene promoters, as indicated. The distal region (approximately 23351 to 23551) of the pS2 gene
promoter was examined for the presence of ERa (bottom row).
F: The recruitment of ERa to the promoter of an estrogen-induced AP-1-dependent gene MMP-1. Soluble chromatin was immunoprecipitated with antibodies
against ERa or c-Fos. The final DNA extractions were amplified using pairs of primers that cover the AP-1 site as indicated or the non-AP-1-specific site (approx-
imately +2555) of the MMP-1 gene promoter.CANCER CELL DECEMBER 2006 491
A R T I C L EFigure 4. DIBA inhibits ERE transactivation
A–C:MCF-7/LCC2 or MCF-7 cells were transfected with a pGL3-TK-ERE luciferase, pGL3-TK-ARE luciferase, or pGL3-AP-1 luciferase construct, respectively. After
addition of 4-OH-TAM (50 nM) and/or DIBA (5 mM) for 2 hr, cells were stimulated with or without 50 nM E2 or 100 nM R1881 for 16 hr. Luciferase activity of lysed
cells was measured and normalized. Data shown represent mean 6 SEM.
D: MDA-MB-468 cells were transfected with a wild-type ER (pSG5-HE0), a series of human ER deletion mutants including pSG5-HE11, pSG5-HE19, pSG5-HE16,
pSG5-HEZF, or pSG5 control plasmids and a pGL3-TK-ERE luciferase reporter. After 24 hr, the transfected cells were treated with DIBA, E2, 4-OH-TAM, and IGF-1
for an additional 24 hr. Luciferase activity of lysed cells was measured and normalized. Data shown represent mean 6 SEM.non-AP-1-specific site in promoter of matrix metalloproteinase
1 (MMP-1), an estrogen-induced/AP-1-dependent gene pro-
moter containing AP-1 sites but no ERE sequences (DeNardo
et al., 2005). DIBA did not affect such occupancy of c-fos or
ERa, consistent with the observation by EMSA.
DIBA inactivates ligand-dependent ERE transactivation
To determine whether DIBA might affect TAM-mediated ER
transcription in TAM-resistant breast cancer cells, we tested
transactivation of MCF-7/LCC2 (Figure 4A) and MCF-7 (Fig-
ure 4B) cells transfected with the ERE-luciferase reporter
gene. E2 activated ERE transactivation in both cell lines. TAM
alone suppressed E2-induced ERE transactivation in MCF-7
cells, whereas it increased ERE transactivation in MCF-7/
LCC2 cells. DIBA significantly reduced ERE transactivation
stimulated by 4-OH-TAM and E2 in MCF-7/LCC2 cells. By con-
trast, DIBA did not affect androgen-responsive element (ARE)492transactivation mediated by R1881 in both MCF-7 and MCF-
7/LCC2 cells (Figures 4A and 4B). Furthermore, DIBA did not
inhibit transactivation of AP-1-luc (Figure 4C). These data indi-
cate that DIBA selectively suppresses TAM-stimulated ER
DNA binding and subsequent ERE transactivation.
To further validate the target specificity of DIBA on ligand-
dependent ERE transcription in TAM-resistant breast cancer
cells, we cotransfected the wild-type human ERa (HE0), a series
of human ER deletion mutants (Kumar et al., 1987) including
HEZF (ER depleted of zinc finger domains, ER-DZF), HE11 (ER
depleted of DBD, ER-DDBD), HE19 (ER depleted of A/B regions
but containing DBD and AF-2 domain, ER-DA/B), HE16 (ER
depleted of D/E/F regions, ER-DD/E/F), or pSG5 control expres-
sion plasmid and the ERE-luciferase reporter gene into the
ER-negative MDA-MB-468 cells. As shown in Figure 4D, over-
expression of ERa, compared to pSG5 control, remarkably
resulted in ERE transactivation. E2 strongly activated ERECANCER CELL DECEMBER 2006
A R T I C L Etransactivation, whereas TAM did not show significant inhibition
on such transactivation. Also, induction of ERE transactivation
by E2 was observed in the cells overexpressed by ERa mutant
HE19 containing completed AF-2 domain and DBD. Deletion
of zinc finger domains (HEZF) or the entire DBD (HE11) resulted
in decreasing ERE transactivation stimulated by E2, suggesting
that zinc fingers in DBD are required for ligand-dependent ERE
transactivation. DIBA significantly enhanced TAM inhibition in
the wild-type ERa- or a mutant HE19 (ER-DA/B)-overexpressing
cells, but not in HE11 (ER-DDBD)- or HEZF (ER-DZF)-overex-
pressing or control cells. Since DIBA, as a zinc finger inhibitor,
has been demonstrated to preferentially disrupt the ER DNA-
binding domain, the inhibitory effect of DIBA on ligand-induced
ERE transcription in TAM-resistant breast cancer cells may be
related to interruption of zinc finger domains within ER-DBD.
DIBA reduces ligand-independent ERE transactivation
The ligand-independent ERE transcription was alsomeasured in
the above wild-type ER or mutant-transfected MDA-MB-468
cells. As shown in Figure 4D, in the case of the wild-type ER
(HE0)-overexpressing cells, IGF-1 strongly induced ERE trans-
activation. Deleting zinc finger domains or the entire DBD
decreased ERE transactivation stimulated by either E2 or
IGF-1, even though this mutant contains completed AF-1 and
AF-2 domains. However, induction of ERE transactivation by
IGF-1 was observed in the cells overexpressed by the ER mu-
tant HE16 containing a completed N-terminal A/B domain and
DBD, suggesting that DBD is required for both ligand-depen-
dent and -independent ERE transactivation. IGF-1’s activation
of ERE transcription is not only dependent on the AF-1 domain
itself, but is also mediated through the interaction between DBD
and AF-1 domains, consistent with previous observations that
long-range allosteric communication occurs in two separated
domains of the androgen receptor (Brodie and McEwan,
2005), glucocorticoid receptor (Kumar et al., 1999), and proges-
terone receptor (Bain et al., 2000).
Moreover, DIBA blocked ERE transactivation stimulated by
IGF-1 in the cells overexpressed by awild-type ER or the ERmu-
tant (HE16) containing A/B/C domains. Such an inhibitory effect
of DIBA was not observed in the ER mutants HE11 (ER-DDBD)-
and HEZF (ER-DZF)-transfected cells, indicating that inhibition
of DIBA on the ‘‘steroid-independent activation’’ of ER by
growth factor signals was related to DBD-mediated intramolec-
ular communicationwith the AF-1 domain, whichmay also be in-
volved in DIBA functionally suppressing TAM-resistant breast
cancer cells.
DIBA decreases the TAM-bound ER association
with AIB1
Activated AIB1 probably translocates to nucleus (Schiff et al.,
2004), where it can interact with ER; therefore, we utilized
a coimmunoprecipitation experiment to analyze whether DIBA
impacts the ERa interaction with AIB1. Cell extracts were immu-
noprecipitated with an anti-ERa-specific antibody; immunopre-
cipitates were developed onwestern blots with anti-AIB1 (upper
panel) or anti-ERa (lower panel). In MCF-7/LCC2 cells (Fig-
ure 5A), the AIB1 can be coprecipitated with ERa in cells treated
with E2, 4-OH-TAM, or IGF-1, indicating that a direct protein-
protein interaction occurs between nuclear receptor ERa
and its coactivator AIB1 upon addition of E2, 4-OH-TAM, and
IGF-1. Notably, DIBA significantly decreased such ERCANCER CELL DECEMBER 2006interaction with AIB1. In contrast, E2, but not TAM, induced
this association between ERa and AIB1 in MCF-7 cells. These
data support that the effect of DIBA on TAM-resistant MCF-7/
LCC2 cells may be through dissociation of the coactivator
AIB1 complexes from TAM-bound ERa.
DIBA increases association of TAM-bound
ERa with NCoR
Several lines of evidence indicate that the nuclear receptor
corepressor (NCoR) complex mediates the inhibitory effects of
TAM (Keeton and Brown, 2005). Thus, we examined whether
DIBA affects NCoR modulation of the response of ERa to TAM
by using a coimmunoprecipitation experiment. Cell extracts
were immunoprecipitated with an anti-NCoR specific antibody;
immunoprecipitates were developed on western blots with anti-
ERa (Figure 5B). In control MCF-7 cells, TAM induced the asso-
ciation between ERa and NCoR while E2 did not affect it, which
maymediate the antagonistic effect of TAMon its sensitive cells.
In MCF-7/LCC2 cells, a little ERa can be coprecipitated with
NCoR, suggesting that a weak constitutive interaction occurs
between nuclear receptor ERa and NCoR, which is consistent
with the previous observations that interactions of ERa with
NCoR in vitro appear to occur regardless of the ligand state of
the receptor (Smith et al., 1997; Voss et al., 2005). Although
E2 and IGF-1 significantly decreased such interaction, TAM
alone did not increase it. DIBA remarkably increased NCoR
association with ERa in the presence of E2, IGF-1, and TAM,
suggesting that effect of DIBA on TAM-resistant MCF-7/LCC2
cells may also occur through association of the corepressor
NCoR complexes with ERa.
DIBA mediates chromatin-associated recruitment
of ERa and cofactors
To examine whether interaction between ERa and AIB1 or ERa
and NCoR is chromatin associated, we performed ChIP assays
of ER followed by the Re-ChIP analysis of either AIB1 or NCoR,
analyzing the assembly of ERa-cofactor complex components
on a well-characterized estrogen-responsive pS2 promoter
(Figure 5C). The soluble chromatin derived from MCF-7/LCC2
cells was subjected to ChIP with ERa antibodies; subsequently,
the released immune complexes were divided into two aliquots
for the Re-ChIP using AIB1 antibodies or NCoR antibodies. The
same Re-ChIP was also performed on the unbound supernatant
fractions from the primary immunoprecipitation. The ChIP assay
of ERa antibodies showed that strong binding of ERa to the
pS2 promoter was induced by E2 or TAM. DIBA significantly
decreased E2- or TAM-occupied ERa binding to the estrogen-
responsive DNA sequences in the pS2 promoter. The Re-ChIP
assay using AIB1 antibodies illustrated that E2 or TAM induced
occupancy of the pS2 promoter by ER and the coactivator AIB1.
However, the Re-ChIP assay using NCoR antibodies showed
that amarginal recruitment of theNCoR occurred in the absence
of ligand, while stimulating E2 or TAM abolished such promoter
occupancy by ERa-NCoR complexes, indicating that interac-
tions between ERa-AIB1 and between ERa-NCoR are chroma-
tin associated. After DIBA treatment, there were very low levels
of E2- or TAM-induced recruitment of ERa-AIB1 and ERa-NcoR
complexes to chromatin. Combined with the data obtained from
coimmunoprecipitation experiments (Figures 5A and 5B), these
results suggested that DIBA-induced changes in ERa associa-
tion with cofactors led to inhibition of ERa binding to DNA, in493
A R T I C L EFigure 5. Effect of DIBA on ERa association with
AIB1 or NCoR
A and B: ERa association with cofactors assayed
by coimmunoprecipitation. MCF-7/LCC2 or
MCF-7 cells were treated with or without DIBA
for 2 hr, and then stimulated with E2, 4-OH-TAM,
or IGF-1 for 24 hr before lyses. A: Western blotting
analysis with anti-AIB1 (upper panel) or anti-ERa
(lower panel) was performed on anti-ERa immu-
noprecipitates. B: Western blotting analysis was
performed with anti-ERa (upper panel) or anti-
NCoR (lower panel) on anti-NCoR immunopre-
cipitates.
C: Recruitment of ERa and cofactors assayed by
ChIP-Re-ChIP. Soluble chromatin was immuno-
precipitated with antibodies against ERa (1 IP).
The supernatant was collected and reimmuno-
precipitated with antibodies against AIB1 or
NCoR (Supernatant Re-IP). Similar reciprocal
Re-IPs were also performed on complexes eluted
from the 1 IPs (Bound Re-IP).
D: Time course of GFP-ERa redistribution. MCF-7/
LCC2 cells were transiently transfected with
pEGFP-C2-hERa. Live cells expressing GFP-ERa
were pretreated with vehicle or DIBA for 2 hr,
followed by stimulation with 50 nM E2 or 50 nM
TAM. Time courses of GFP-ER distribution were
analyzed at 10 min intervals. Scale bar, 5 mm.turn blocking transcription of target genes, which aided the
synergism between DIBA and TAM.
Since cofactor association can influence ERa cellular localiza-
tion, we used a transcriptionally active green fluorescent pro-
tein-ERa chimera (GFP-ERa) to examine whether DIBA affects
ERa cellular distribution. MCF-7/LCC2 cells were transiently
transfected with pEGFP-C2-hERa, and live cells expressing
GFP-ERawere analyzed at 10min intervals under confocal laser
scanning microscopy. Without ligand, GFP-ERa was observed
only in the nucleus, excluding the nucleolus, with a diffuse dis-
tribution. Upon adding E2, GFP-ERa was dramatically redistrib-
uted from a reticular to punctate pattern within the nucleus (Fig-
ure 5D). A similar reorganization occurred with TAM. In the cells
pretreated with DIBA, neither E2 nor TAM produced the above
apparent subnuclear redistribution patterns. These results dem-
onstrated that DIBA inhibited E2- or TAM-induced ERa nuclear
distribution.
DIBA dephosphorylates ERa at serine-167,
but not serine-118
The human ERa AF-1 function is potentiated by the phosphory-
lation of serine residues of human ERa A/B domain after stimu-
lation with its ligands and nonsteroidal growth factors (EGF and
IGF-1) (Lannigan, 2003; Yamashita et al., 2005). We thus inves-
tigated whether DIBA may modulate ERa phosphorylation by494using site-specific antiphosphoserine antibodies against ERa
at Ser-118 or Ser-167 (Figure 6A). E2, 4-OH-TAM, and IGF-1
stimulated Ser-167 phosphorylation, whereas there was no sig-
nificant difference in the level of phosphorylation of ERa at Ser-
118 inMCF-7/LCC2 cells with the above treatments. While DIBA
inhibited phosphorylation of ERa at Ser-167 induced by all stim-
uli, it affected neither Ser-118 phosphorylation nor the expres-
sion of ERa. It has been demonstrated that ERa phosphorylation
at Ser-167, but not at Ser-118, conferred DNA binding and tran-
scriptional activation (Joel et al., 1998) aswell as TAM resistance
(Campbell et al., 2001). Since the structure of the N-terminal
AF-1 domain appears to be influenced by the DBD (Graham
et al., 2000), and DIBA selectively reacts with zinc finger of
ER-DBD, it seems likely that DIBA may interfere with phos-
phorylation of Ser-167 in AF-1 proximal to the DBD site through
intramolecular communication, concurring with the above
observation on the effect of DIBA in ligand-independent ERE
transactivation (Figure 4D), and may also contribute to DIBA
sensitizing the resistant cells to TAM.
DIBA does not affect expression and phosphorylation
of AIB1 and MAPK
Since ER coactivator AIB1, like ER itself, is phosphorylated and
activated by different signaling kinases, including the p42/44
MAPK, which can be activated by HER2 (Font de Mora andCANCER CELL DECEMBER 2006
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phorylation of AIB1 in TAM-resistant cells (Figure 6B). MCF-7/
HER2-18 cell extracts were immunoprecipitated with an anti-
AIB1 specific antibody; the immunoprecipitates were developed
on western blots with anti-phosphoserine (upper panel), anti-
phosphotyrosine (middle panel), or anti-AIB1 (lower panel).
The phosphorylation of serine, but not tyrosine, of AIB1 could
be observed in cells stimulated with E2, 4-OH-TAM, and EGF.
However, DIBA did not affect such phosphorylation, indicating
that DIBA inactivates ER Ser-167 phosphorylation, but does
not affect expression and phosphorylation of AIB1, possibly
due to AIB1’s lacking a zinc finger, although the signaling from
the EGFR/HER2 family activates ER and AIB1 by the p42/44
MAPK.
We further examined whether DIBA disrupted phosphoryla-
tion of MAPK in different TAM-resistant breast cancer cell lines.
Figure 6C shows the same pattern for the phosphorylation of
MAPK as that for AIB1 in MCF-7/HER2-18 cells. Similar results
Figure 6. Effect of DIBA on expression and phosphorylation of ERa, AIB1, and
MAPK
A: MCF-7/LCC2 cells were treated with or without DIBA for 2 hr, then simu-
lated with E2, 4-OH-TAM, or IGF-1 for 20 min before lyses. Western blotting
analysis was performed with anti-phospho-ER (Ser-167 or Ser-118) or anti-ER.
B: MCF-7/HER2-18 cell lysates were immunoprecipitated with anti-AIB1. Im-
munoprecipitates were blotted with anti-phosphoserine (upper panel),
anti-phosphotyrosine (middle panel), or anti-AIB1 (lower panel).
CandD:Cell lysates of MCF-7/HER2-18 (C), MCF-7/LCC2, and BT474 (D) were
analyzed with anti-phospho-MAPK for blot (upper panel) or anti-MAPK
(lower panel) for re-blot.CANCER CELL DECEMBER 2006were observed in MCF-7/LCC2 and BT474 cells (Figure 6D); the
ratio of phospho-MAPK to total MAPK was not significantly
changed after the treatment with DIBA.
DIBA does not influence expression and phosphorylation
of HER2 and AKT
Since overexpression of HER2 and high levels of phosphory-
lated AKT may also contribute to TAM resistance (Gutierrez
et al., 2005; Osborne et al., 2003), we examined whether DIBA
disrupted expression and phosphorylation of HER2 and AKT
in TAM-resistant breast cancer cell lines. Compared to MCF-7
cells, MCF7/HER2-18, MCF-7/LCC2, and BT474 cells ex-
pressed a considerable level of HER2 (Figures 7A and 7B). There
are no significant changes in HER2 expression in DIBA-treated
cells. Moreover, even though TAM and IGF-1 induced remark-
able phosphorylation of HER2 (Stoica et al., 2000), DIBA did
not affect it (Figure 7B), nor did DIBA significantly affect TAM-
or IGF-1-stimulated phosphorylation of AKT (Figure 7C) in
MCF-7/LCC2 cells. These results indicate the inhibitory effect
of DIBA on TAM-resistant cell proliferation is not based on inac-
tivation of HER2, MAPK, and PI3-K/AKT.
Figure 7. Effect of DIBA on expression and phosphorylation of HER2 and AKT
A: MCF-7, MCF-7/LCC2, and MCF-7/HER2-18 cells were treated with DIBA for
2 hr and then stimulated with E2, 4-OH-TAM, or IGF-1 for 20 min. HER2 expres-
sion was analyzed by western blotting with anti-HER2.
B: MCF-7/LCC2, MCF-7/HER2-18, and BT474 cells were treated as described
in A, except that the antibodies were anti-phospho-HER2 for blot (upper
panel) or anti-HER2 for re-blot (lower panel).
C: MCF-7/LCC2 cells were treated as described in A, except that the anti-
bodies were anti-phospho-AKT for blot or anti-AKT for re-blot.495
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ER plays amajor role in many cases of breast cancer and appar-
ently contributes to the growth of TAM-responsive, acquired
TAM-resistant, and de novo ER-positive resistant models (Gee
et al., 2005). By using siRNA to deplete ER of BT474, an ER-pos-
itive but TAM-resistant breast cancer cell line, we found that
DIBA rendered TAM inhibition on parent ER-positive cells, but
not on ER-depleted breast cancer cells (Figure 3A), suggesting
that DIBA function on TAM-resistant breast cancer cells is ER
dependent. We previously discovered that DIBA preferentially
disrupted the vulnerable zinc fingers of the ERa DNA-binding
domain, thus blocking ER DNA binding and transactivation
(Wang et al., 2004). In this study, we used chromatin immuno-
precipitations to directly assess ER binding to DNA on estrogen
target genes. Stimulation with E2 and TAM dramatically in-
creased ER’s occupancy of the pS2, c-Myc, and CATD gene
promoters. DIBA remarkably decreased such occupancy of
ER to the target DNA sequences in chromatin (Figure 3E). These
results suggested DIBA directly influences the ability of ER to
bind to DNA, consistent with the data obtained from EMSA
(Figure 3B). Moreover, DIBA resulted in inhibition of ligand-
dependent and -independent ERE transactivation (Figure 4D).
Therefore, targeted disruption of ER is necessary for DIBA,
a zinc finger inhibitor, to sensitize TAM inhibition of resistant
breast cancer cells through interfering with ER DNA binding
and subsequent ERE transactivation.
Nuclear receptor function is modulated by transcriptional cor-
egulators (Klinge et al., 2004; McKenna and O’Malley, 2002;
Shang et al., 2000; Shang and Brown, 2002; Tikkanen et al.,
2000). The relative level of these coactivators and corepressors
might determine the balance of agonist and antagonist proper-
ties of TAM. Here, we used coimmunoprecipitation to clarify that
DIBA decreased physical association of TAM-bound ER with its
coactivator AIB1 (Figure 5A), whereas it increased ER interac-
tion with its corepressor NCoR (Figure 5B). Moreover, ChIP ex-
periments of ERa followed by either Re-ChIP of AIB1 or NCoR
also showed that effect of DIBA on E2- or TAM-induced associ-
ation between ER and AIB1 and dissociation between ERa and
NCoR in the level of chromatin (Figure 5C), suggesting that
DIBA-mediated changes in ERa interaction with cofactors
resulted in blockage of TAM-bound ERa binding to targeted
gene promoter and transcription. Notably, the ER-cofactor
association caused by DIBA further influences TAM-bound ER
nuclear distribution (Figure 5D), indicating other functional
changes of ERa may have with chromatin on/off rates or shut-
tling. The above molecular mechanisms, by which the syner-
gism between DIBA and TAM impacted ER activity, contributed
to DIBA restoring TAM’s antagonist action on TAM-resistant
breast cancer cells (Figures 1 and 2). It may be important to
note that in our previous report, the ED50 for DIBA ejection of
zinc from recombinant ERa was 25 mM (Wang et al., 2004).
Here we show effects on disrupting ERa/AIB1 or enhancing
ERa/NCoR functions at 5-fold less, 5 mM, suggesting a range
of molecular effects on ERa functions.
Several peptide growth factors and their intracellular signaling
kinases, notably MAPK and AKT (Albanell and Baselga, 2001),
have been shown to mediate cell proliferative responses and
phosphorylate ERa on various AF-1 residues, promoting ERa
transcriptional activity in a ligand-independent manner (Martin
et al., 2000). In the case of TAM-resistant cells, we observed496that exogenous IGF-1 stimulated phosphorylation of MAPK and
AKT as well as ERa. Although DIBA did not affect phos-
phorylation of ERa at Ser-118, MAPK, or AKT, DIBA markedly
inhibited phosphorylation of ERa at Ser-167 (Figure 6A), sug-
gesting that inhibitory effects of DIBA on a powerful functional
crosstalk engaged by the IGF-1 and ER pathways may occur
through dephosphorylating ERa at Ser-167. Thus, DIBA disrup-
tion of ER zinc fingers resulted in not only perturbing DBD-
dependent ERE transactivation (Figures 4A–4D), but also inter-
fering with intramolecular communication between DBD and
the N-terminal AF-1 domain (Figure 4D) to downregulate phos-
phorylation of Ser-167 (Figure 6A) induced by nonestrogenic
stimulation in TAM-resistant breast carcinoma cells.
Overexpression of HER2 and high levels of phosphorylated
AKT or ERK1/2 MAPK may also contribute to TAM resistance.
MCF-7 cells stably transfected with HER2 (MCF-7/HER2-18)
are de novo resistant to TAM, in contrast to their low-expressing,
responsive MCF-7 counterparts (Benz et al., 1993; Konecny
et al., 2003; Shou et al., 2004). Importantly, EGFR/HER2 signal-
ing remains dependent on the ER in MCF-7/HER2-18 cells, as
evidenced by their retained sensitivity to estrogen deprivation
(Shou et al., 2004). DIBA did not inhibit phosphorylation of
HER2, MAPK, and AKT (Figures 6 and 7) or of the coactivator
AIB1 (Figure 6B). Moreover, DIBA did not display suppression
of estrogen- or TAM-induced DNA binding (Figures 3D and 3F)
and transactivation for AP-1 (Figures 3F and 4C), a nontypical
ER-binding site. These results suggested that nongenomic ac-
tions of ERa may be not involved in the synergism between
DIBA and TAM. However, this idea can not be totally excluded;
most of the data suggest that DIBA blocks classical genomic
sites of ERa.
In conclusion, DIBA resulted not only in inhibition of ligand-de-
pendent ERa DNA binding and transcription, but also in effects
on ligand-independent ERE transactivation. Of particular impor-
tancewas the synergismbetweenDIBA and TAM in regulating re-
cruitment of cofactors to chromatin (decreasing the interaction of
ERawith AIB1 and blocking dissociation between ERa andNCoR
caused by E2 or TAM). Consequently, DIBA restores the antago-
nistic action of TAM in breast cancer cells that have acquired re-
sistance, in turn quenching target gene expression and blocking
cell growth of TAM-resistant breast cancer cells. These studies
suggest a possible new approach in modifying TAM resistance
and a potential role for small electrophilic compounds that can
modify the particularly vulnerable zinc finger in ERa.
Experimental procedures
Cell and cell culture
The electrophilic compound DIBA (NSC654077) was from the Laboratory of
Cell Biology, National Cancer Institute. The humanbreast carcinoma cell lines
MCF-7, ZR-75, andMDA-MB-468were obtained fromATCC (Manassas, VA).
The MCF-7/LCC2 cell line was from Dr. R. Clarke. MCF-7/HER2-18 and
BT474 cell lines were from Dr. K. Osborne. 4-OH-TAM and 17b-Estrodial
werepurchased fromSigma-Aldrich (St Louis,MO). ICI 182780was fromToc-
ris (Ellisville, MO). In experiments with estrogen or TAM, cells were cultured in
phenol red-free and DMEM or RPMI 1640 supplemented with 5% charcoal-
dextran-stripped fetal calf serum for at least 2 days.
Cell proliferation and cell-cycle analysis
Cell proliferation was examined by measuring DNA synthesis with [3H]thymi-
dine uptake (Wang et al., 2004). Cell cycle was analyzed by propidium iodide
staining and FACS (Li et al., 2006).CANCER CELL DECEMBER 2006
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Electrophoretic mobility shift assay (EMSA) was performed as described
previously (Wang et al., 2003). End-labeled [32P] oligonucleotide probes
correspond to the ERE consensus sequence: 50-GATCCGTCAGGTCAC
AGTGACCTGATGGATC-30, ARE consensus: 50-GAAGTCTGGTACAGG
GTGTTCTTTTTG-30, and AP-1 consensus: 50-CGCTTGATGAGTCAGCCG
GAA-30, respectively.
Expression plasmids
pSG5-HE0, pSG5-HE11, pSG5-HE16, or pSG5-HE19 expression plasmids
were kindly provided by Dr. P. Chambon, Universit _e Louis Pasteur, France.







AGGGAAACCCTCTGCCTCCCCC-30 resulting in deletion of amino acids
185–205 and 221–245.
Transfection of SiRNA for ERa
BT474 cells were transfected with an ERa-SiRNA construct or control vector
for 96 hr according to themanufacturer’s instructions (NewEngland BioLabs,
MA). Efficacy of the constructs was tested through western blot analysis of
the respective target ERa in transfected cells.
Transfection of luciferase reporter plasmids
FuGene-6 was used for transfection of luciferase reporter plasmids or
cotransfection of reporter gene plasmidswith ER expression plasmids. Lucif-
erase assays were performed according to the manufacturer’s instructions
(BD PharMingen, San Diego, CA).
Coimmunoprecipitation and western blot analysis
Coimmunoprecipitation and western blots were performed as previously
described (Yang et al., 2000). Antibodies against ER, phospho-ER, AIB1,
phospho-AIB1, NCoR, HER2, phospho-HER2, AKT, phospho-AKT, MAPK,
phospho-MAPK, phosphotyrosine, and phosphoserine were from Upstate
Biotechnology (Lake Placid, NY).
Chromatin immunoprecipitation
The ChIP assays were based on a protocol described by Shang et al. (2000).
Cells were fixed by formaldehyde. Purified chromatin samples were immuno-
precipitated with anti-ERa antibody. DNA, isolated from immunoprecipitated
material following reversal of formaldehyde crosslinking, was amplified by
PCR. Promoter-specific primers included: pS2, 50-CCGGCCATCTCTCAC
TAT-30 (forward primer) and 50-ATCTTGGCTGAGGGATCT-30 (reverse
primer); pS2 upstream primer pair for negative control, 50-GAAGACTCCG
CACCTCAGAC-30 (forward primer) and 50-CCCTTGTGGGGAATCTGG-30
(reverse primer); c-Myc, 50-CCGCCTGCGATGATTTATAC-30 (forward
primer) and 50-AAGGTGGGGAGGAGACTCAG-30 (reverse primer); Cathep-
sin D, 50-TCCAGACATCCTCTCTGGAA-30 (forward primer), 50-GGAGCGG
AGGGTCCATTC-30 (reverse primer). MMP-1 promote, 50-TTGCAACACCAA
GTGATTCCA-30 (forward primer) and 50-CCCAGCCTCTTGCTACTCCA-30
(reverse primer); MMP-1 non-AP-1 specific site, 50-GAGTACAACTTACA
TCGTGTTGCAG-30 (forward primer) and 50-ATATGGCTTGGATGCCATCA
ATGTC-30 (forward primer).
ChIP Re-ChIP
Complexes were eluted from the primary immunoprecipitation by incubation
with 10 mM DTT at 37C for 30 min and diluted 1:50 in buffer (1% Triton
X-100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris-HCl [pH 8.1]), followed by
reimmunoprecipitation with the second antibodies (Shang et al., 2000).
ChIP Re-ChIPs of supernatants were done essentially as the primary IPs.
Live microscopy
MCF-7/LCC2 cells were grown on 14 mm coverslips in 35 mm plates and
transfectedwith a pEGFP-C2-hERa construct using FuGene-6. Before ligand
addition, the starved cells were pretreated with DIBA for 2 hr. Images wereCANCER CELL DECEMBER 2006acquired at 10min intervals with a Zeiss LSM 510 confocal microscope using
a 403/1.3 NA oil immersion objective lens (Stenoien et al., 2000).
Human tumor xenografts
Human MCF-7/LCC2-derived tumor xenografts were established in female
athymic Ncr-nu/nu nude mice (National Cancer Institute, Frederick, MD) as
described previously (Brunner et al., 1993; Wang et al., 2004). Tumor volume
is calculated as a23 b 3 0.5, where ‘‘a’’ is the width and ‘‘b’’ is the length of
the tumor. Formalin-fixed tissue sections were embedded in paraffin, stained
with hematoxylin and eosin, and examined under a light microscope. Animal
experimentation was reviewed and approved by NCI’s Animal Research
Committee.
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